Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition

Mayo Clinic Proceedings

Volumn 87, Issue 11, 2012, Pages 1071-1079

  Therneau, Terry M ^a   Kyle, Robert A ^a   Melton III, L Joseph ^a   Larson, Dirk R ^a   Benson, Joanne T ^a   Colby, Colin L ^a   Dispenzieri, Angela ^a   Kumar, Shaji ^a   Katzmann, Jerry A ^a   Cerhan, James R ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; PREVALENCE; SEX RATIO; UNITED STATES; HEALTH STATUS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINNESOTA; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84872251513     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.06.014     Document Type: Article

References (14)

1. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
3. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-5417.
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
5. Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York, NY: Chapman & Hall; 1990. Monographs on Statistics and Applied Probability.
6. Morton A, Finkenstädt BF. Discrete time modelling of disease incidence time series by using Markov chain Monte Carlo methods. J R Stat Soc Ser C Appl Stat. 2005;54(3):575-594.
7. Bray I. Application of Markov chain Monte Carlo methods to projecting cancer incidence and mortality. J R Stat Soc Ser C Appl Stat. 2002;51(2):151-164.
8. Podgor MH, Leske MC. Estimating incidence from age-specific prevalence for irreversible disease with differential mortality. Stat Med. 1986;5(6):573-578.
9. Keiding N. Age-specific Incidence and prevalence: a statistical perspective. J R Stat Soc Ser A. 1991;154(3):371-412.
10. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
11. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64(5):814-826.
12. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20(6):1138-1144.
13. Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2009; 15(18):5606-5608.
14. Harris TE. The Theory of Branching Processes. Heidelberg, Germany: Springer-Verlag; 1963.